(-0.58%) 5 022.21 points
(-0.12%) 37 753 points
(-1.15%) 15 683 points
(-2.99%) $82.81
(-1.04%) $1.714
(-0.86%) $2 387.10
(-0.09%) $28.35
(-2.21%) $953.60
(-0.48%) $0.937
(0.20%) $11.00
(-0.22%) $0.803
(-0.08%) $94.07
Live Chart Being Loaded With Signals
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension...
Stats | |
---|---|
Today's Volume | 8 391.00 |
Average Volume | 31 803.00 |
Market Cap | 60.58M |
EPS | €0 ( 2023-09-28 ) |
Next earnings date | ( €0 ) 2024-04-28 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -4.52 |
ATR14 | €0.0200 (0.52%) |
Volume Correlation
Valbiotis SA Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Valbiotis SA Correlation - Currency/Commodity
Valbiotis SA Financials
Annual | 2022 |
Revenue: | €785 000 |
Gross Profit: | €767 000 (97.71 %) |
EPS: | €-1.220 |
Q2 | 2023 |
Revenue: | €4.24M |
Gross Profit: | €4.24M (100.00 %) |
EPS: | €-0.160 |
Q4 | 2022 |
Revenue: | €150 000 |
Gross Profit: | €150 000 (100.00 %) |
EPS: | €-0.690 |
Q2 | 2022 |
Revenue: | €635 000 |
Gross Profit: | €635 000 (100.00 %) |
EPS: | €-0.520 |
Financial Reports:
No articles found.
Valbiotis SA
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators